Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
Conference reports
2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports, Cure-related research.
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA
1 August 2016. Related: Conference reports.
Modelling data might support use of low dose 400 mg efavirenz in pregnancy
1 August 2016. Related: Conference reports, Pregnancy.
Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery
1 August 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
22nd Annual BHIVA Conference, 19-22 April 2016, Manchester
1 June 2016. Related: Conference reports.
New HBV drugs and non-viral liver disease in HIV positive people
1 June 2016. Related: Conference reports, Hepatitis coinfection, Basic science and immunology.
Non-AIDS mortality in England and Wales in HIV positive vs general population
1 June 2016. Related: Conference reports, Ageing and life expectancy, Research studies.
High prevalence of multiple high-risk HPV infections in young HIV positive gay men
1 June 2016. Related: Conference reports, Coinfections and complications, Vaccines and microbicides.
Anal cancer and HPV screening in HIV positive people
1 June 2016. Related: Conference reports, Cancer and HIV, Vaccines and microbicides.
Increasing demand for community treatment information services
1 June 2016. Related: Conference reports.
Non alcohol fatty acid liver disease: an emerging problem
1 June 2016. Related: Conference reports, Coinfections and complications.
HIV positive people on ART have impaired alveolar immunity
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona
1 June 2016. Related: Conference reports.
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
1 June 2016. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
1 June 2016. Related: Conference reports.
No effect of tenofovir on infant bone mineral content in African study
1 June 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Nevirapine dosing for treatment of neonates
1 June 2016. Related: Conference reports, Paediatric care, PK and drug interactions.
START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
1 June 2016. Related: Conference reports, Hepatitis coinfection.
6th International Workshop on HIV & Women, 20-21 February 2016, Boston
1 June 2016. Related: Conference reports.
Doravirine can be co-administered with oral contraceptives
1 June 2016. Related: Conference reports, Women's health.
No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry
1 June 2016. Related: Conference reports, Pregnancy.
23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
22 March 2016. Related: Conference reports.
Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study
22 March 2016. Related: Conference reports, Antiretrovirals.
New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP
22 March 2016. Related: Conference reports, Antiretrovirals.
Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART
22 March 2016. Related: Conference reports, Antiretrovirals.
48-week results for NNRTI doravirine compared to efavirenz
22 March 2016. Related: Conference reports, Antiretrovirals.
Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots
22 March 2016. Related: Conference reports, HIV prevention and transmission.
First data on TAF as PrEP to prevent HIV infection
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Role for maraviroc as HIV PrEP likely to need dual combinations
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women
22 March 2016. Related: Conference reports, HIV prevention and transmission, Vaccines and microbicides.
Early data from dolutegravir use during pregnancy
22 March 2016. Related: Conference reports, Pregnancy.
Dolutegravir: 48 week results in children age 6 to 12 years old
22 March 2016. Related: Conference reports, Paediatric care.
New antiretrovirals could mean savings up to US $3 billion by 2025
22 March 2016. Related: Conference reports, Treatment access.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
22 March 2016. Related: Conference reports, Antiretrovirals.
Cure research news from CROI 2016
22 March 2016. Related: Conference reports, Cure-related research.
46th World Conference on Lung Health of the International Union Against TB and Lung Disease
1 February 2016. Related: Conference reports.
Promising first results with a 9-month regimen for multidrug resistant tuberculosis in French-speaking African countries
1 February 2016. Related: Conference reports, TB coinfection.
Pharmacokinetics of old and new TB drugs for children
1 February 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants
1 February 2016. Related: Conference reports, TB coinfection.
BHIVA Autumn Conference 2015, 12-13 November 2015, London
1 February 2016. Related: Conference reports.
Selected webcasts from BHIVA Autumn conference 2015
1 February 2016. Related: Conference reports, On the web.
15th European AIDS Conference (EACS), 21-24 October 2015, Barcelona
1 December 2015. Related: Conference reports.
Remarkable results with dolutegravir monotherapy
1 December 2015. Related: Conference reports, Antiretrovirals, Vaccines and microbicides.
First-line ART with dolutegravir plus 3TC: 24-week early results
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
New European HIV guidelines (October 2015): universal ART, first-line integrase and PrEP
1 December 2015. Related: Conference reports, Guidelines.
Impact of early ART on lung function: results on ART and COPD from START substudy
1 December 2015. Related: Conference reports, Coinfections and complications.
No difference in neuropsychological test results between early and delayed ART in START substudy
1 December 2015. Related: Conference reports, Side effects, Coinfections and complications.
Immediate ART in START linked to greater bone loss over three years
1 December 2015. Related: Conference reports, Side effects.
Price of MDR TB drugs could be greatly reduced with competitive generic manufacture
1 December 2015. Related: Conference reports, Treatment access, TB coinfection.
Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23
1 December 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
French cohort of HIV transgender women highlights issues relating to HIV management
1 December 2015. Related: Conference reports.
7th International Workshop on HIV Paediatrics, 17-18 July, Vancouver, Canada
1 December 2015. Related: Conference reports.
Substituting lopinavir/ritonavir with efavirenz in children on stable ART
1 December 2015. Related: Conference reports, Antiretrovirals, Paediatric care.
The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression
1 December 2015. Related: Conference reports, Paediatric care, PK and drug interactions.
Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB
1 December 2015. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-21 September 2015, San Diego
1 October 2015. Related: Conference reports.
No transmission of integrase-resistant HIV seen in California cohort
1 October 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Drug resistance.